or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor does not have an abnormal “EGFR,” “ALK,” or “ROS1” gene. LIBTAYO may be used as your first …

Oct 27, 2024 · Libtayo may also be used along with a platinum-based chemotherapy as an initial (first-line) treatment for advanced or metastatic NSCLC that does not have other targetable mutations of …

LIBTAYO may be used as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your …

Sep 16, 2024 · These results come from the final prespecified overall survival analysis of the Phase 3 EMPOWER-Lung 1 trial, which compared Libtayo’s monotherapy with chemotherapy as a first-line …

Sep 9, 2025 · The five-year results for Libtayo plus chemotherapy presented at WCLC add to the breadth of long-term data for Libtayo in advanced NSCLC, including five-year outcomes from the …

LIBTAYO in combination with platinum-based chemotherapy is indicated for the first-line treatment of adult patients with non–small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations, …

Nov 30, 2024 · This comprehensive study, spanning over a decade, provides crucial insights into the clinical characteristics, treatment patterns, and resistance mechanisms of advanced ALK-positive …

Libtayo® (cemiplimab-rwlc) is approved to treat certain cases of advanced non-small cell lung cancer (NSCLC). Learn how Libtayo works to treat lung cancer.

Nov 14, 2023 · An chemotherapy and immunotherapy combination, consisting of a platinum-based chemotherapy drug and Libtayo was just approved by the FDA as a frontline treatment for a …

For a type of lung cancer called non–small cell lung cancer (NSCLC) in adults that has spread to other areas of your body or has not spread outside of your chest and cannot be treated with surgery, or …